Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 358 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma October 19, 2026 The Unique Challenges Teenagers and Young Adults With Cancer Face: An... January 4, 2021 Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth January 6, 2020 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Load more HOT NEWS Foodie Fridays-Gazpacho: A Favorite Summer Soup DIY Mosquito Traps & Deterrents (That Really Work) What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread
